High adherence to trientine tetrahydrochloride among U.S. patients with Wilson disease: A nationwide specialty pharmacy analysis

Background: Wilson disease (WD) is a rare inherited disorder of copper metabolism requiring lifelong therapy. Medication adherence may be challenging given the dosing complexity, meal-timing requirements, and medication storage demands associated with approved therapies, which may compromise copper control and disease progression. Trientine tetrahydrochloride (TETA-4HCl) is a twice-daily oral copper chelator distributed in the United States through a single-source specialty pharmacy with patient services. This study evaluated medication adherence to TETA-4HCl using specialty pharmacy dispensing data. Methods: We conducted a retrospective observational analysis of de-identified specialty pharmacy dispensing data for patients prescribed TETA-4HCl between May 2023 and December 2024. Medication adherence was assessed using proportion of days covered (PDC) and mean gap days per shipment. Patient demographics, prescriber specialty, prior therapies, and reasons for treatment discontinuation were summarized descriptively. Results: A total of 142 patients were included (55% male; mean age 39 y). Prescriptions were primarily written by hepatologists (64%) and gastroenterologists (23%), and 32% of patients traveled out of state for care. Nearly all patients (98.6%) received prior WD therapy, and 46% received more than one prior treatment. Among 93 patients with ≥180 days of follow-up, mean PDC was 84%, and 74% achieved PDC ≥80%. Among 126 patients and 1682 shipments (mean 13), mean gap days were 2.7. Twenty-four patients (16.9%) discontinued therapy during the study period, four (2.8%) due to adverse events. Conclusion: In this real-world U.S. cohort, adherence to TETA-4HCl dispensed from a single-source specialty pharmacy with a coordinated centralized distribution and patient support model was high. Further studies integrating pharmacy data with clinical, biochemical, and patient-reported outcomes are needed to evaluate long-term disease outcomes.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-11-20
DOI
https://doi.org/10.1097/hc9.0000000000001079
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High adherence to trientine tetrahydrochloride among U.S. patients with Wilson disease: A nationwide specialty pharmacy analysis

Veronica Tomor, Peter Hedera, C. Omar F. Kamlin, Nick Manamley et al.
Hepatology Communications
Medication Adherence and Compliance
article

High adherence to trientine tetrahydrochloride among U.S. patients with Wilson disease: A nationwide specialty pharmacy analysis

Veronica Tomor, Peter Hedera, C. Omar F. Kamlin, Nick Manamley, Fred K. Askari, Amanda C. Cheung, Amy E. Brown, Jamie Heise, Christina Dockery
article en

Abstract

Background: Wilson disease (WD) is a rare inherited disorder of copper metabolism requiring lifelong therapy. Medication adherence may be challenging given the dosing complexity, meal-timing requirements, and medication storage demands associated with approved therapies, which may compromise copper control and disease progression. Trientine tetrahydrochloride (TETA-4HCl) is a twice-daily oral copper chelator distributed in the United States through a single-source specialty pharmacy with patient services. This study evaluated medication adherence to TETA-4HCl using specialty pharmacy dispensing data. Methods: We conducted a retrospective observational analysis of de-identified specialty pharmacy dispensing data for patients prescribed TETA-4HCl between May 2023 and December 2024. Medication adherence was assessed using proportion of days covered (PDC) and mean gap days per shipment. Patient demographics, prescriber specialty, prior therapies, and reasons for treatment discontinuation were summarized descriptively. Results: A total of 142 patients were included (55% male; mean age 39 y). Prescriptions were primarily written by hepatologists (64%) and gastroenterologists (23%), and 32% of patients traveled out of state for care. Nearly all patients (98.6%) received prior WD therapy, and 46% received more than one prior treatment. Among 93 patients with ≥180 days of follow-up, mean PDC was 84%, and 74% achieved PDC ≥80%. Among 126 patients and 1682 shipments (mean 13), mean gap days were 2.7. Twenty-four patients (16.9%) discontinued therapy during the study period, four (2.8%) due to adverse events. Conclusion: In this real-world U.S. cohort, adherence to TETA-4HCl dispensed from a single-source specialty pharmacy with a coordinated centralized distribution and patient support model was high. Further studies integrating pharmacy data with clinical, biochemical, and patient-reported outcomes are needed to evaluate long-term disease outcomes.

Hepatology CommunicationsVol. 10(12)
Northwestern University (US), University of Louisville (US), Vanderbilt University (US), University of Michigan (US), Michigan Medicine (US), Vanderbilt Health (US)
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon